SCHEMBL15212145

SCHEMBL15212145

COc1ccc(Br)cc1S(=O)(=O)Nc1nccs1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PKM P14618 3/20 0.64
KMT2A Q03164 2/20 0.64
MEN1 O00255 1/20 0.64
ALDH1A1 P00352 1/20 0.64
ALPL P05186 5/20 0.57
GLA P06280 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
EDNRB P24530 2/20 0.53
EDNRA P25101 2/20 0.53
WDR5 P61964 2/20 0.53
KDM4E B2RXH2 1/20 0.53
GAA P10253 1/20 0.53
SCN9A Q15858 3/20 0.52
USP2 O75604 1/20 0.50
MAPT P10636 1/20 0.50
ESR2 Q92731 1/20 0.50
HSD17B10 Q99714 1/20 0.50
MYC P01106 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15211773 0.86 PKM (0.65) PKMKMT2AMEN1ALDH1A1ALPL
SCHEMBL15212020 0.79 PKM (0.71) PKMKMT2AMEN1ALDH1A1ALPL
SCHEMBL15211869 0.78 ALPL (0.71) ALPL
SCHEMBL712317 0.78 SCN9A (0.60) SCN9AUSP2MAPTESR2HSD17B10
SCHEMBL15220373 0.78 EDNRB (0.56) PKMKMT2AALDH1A1ALPLGLA
SCHEMBL712204 0.77 ALPL (0.59) PKMKMT2AMEN1ALDH1A1ALPL
SCHEMBL15834037 0.77 ALOX12 (0.49) PKMKMT2AMEN1ALDH1A1SCN9A
SCHEMBL15212280 0.75 PKM (0.59) PKMKMT2AALPLGLASMN1; SMN2
SCHEMBL713884 0.75 SCN9A (0.52) KMT2AALDH1A1SMN1; SMN2EDNRAKDM4E
SCHEMBL16375022 0.75 KDM4E (0.59) PKMKMT2AALPLGLASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10370333-B2 Sulfonamide compounds and uses as TNAP inhibitors SANFORD-BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE (US) 2019-08-06 US disclosed
US-10370333-B2 Sulfonamide compounds and uses as TNAP inhibitors SANFORD-BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE (US) 2019-08-06 US disclosed
US-20190010126-A1 SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS Sanford Burnham Prebys Medical Discovery Institute 2019-01-10 US disclosed
US-9884826-B2 Sulfonamide compounds and uses as TNAP inhibitors SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2018-02-06 US disclosed
US-9884826-B2 Sulfonamide compounds and uses as TNAP inhibitors SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2018-02-06 US disclosed
US-20160355479-A1 SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE 2016-12-08 US disclosed
US-20160355479-A1 SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE 2016-12-08 US disclosed
US-9458147-B2 Sulfonamide compounds and uses as TNAP inhibitors SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2016-10-04 US disclosed
US-9458147-B2 Sulfonamide compounds and uses as TNAP inhibitors SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2016-10-04 US disclosed
US-20150011551-A1 SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS Sanford- Burnham Medical Reseach Institute (US) 2015-01-08 US disclosed
US-20150011551-A1 SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS Sanford- Burnham Medical Reseach Institute (US) 2015-01-08 US disclosed
EP-2817292-A1 SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS Sanford-Burnham Medical Research Institute (US) 2014-12-31 EP disclosed
WO-2013126608-A1 SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2013-08-29 WO disclosed
WO-2013126608-A1 SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2013-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10370333-B2 Sulfonamide compounds and uses as TNAP inhibitors TNNI3, TNKS1BP1, TNNT2 PKM 2524/4885KMT2A 857/4885MEN1 4072/4885
US-20150011551-A1 SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS TNNI3, TNKS1BP1, TNNT2 PKM 2524/4885KMT2A 857/4885MEN1 4072/4885
US-20190010126-A1 SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS TNNI3, TNKS1BP1, TNNT2 PKM 2524/4885KMT2A 857/4885MEN1 4072/4885
US-20160355479-A1 SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS TNNI3, TNKS1BP1, TNNT2 PKM 2524/4885KMT2A 857/4885MEN1 4072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.